State Street Increases Stake in Avadel Pharmaceuticals, Holding Reaches 2.36%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Increased Stake: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 14, 2026, holding 2,298,063 shares, which represents 2.36% of total shares, indicating ongoing confidence in the company.
- Transaction Details: In this transaction, State Street purchased 6,500 shares at $21.50 each while simultaneously selling the same number of shares, reflecting an active trading strategy in the market.
- Market Impact Analysis: This increase in stake may positively influence Avadel's stock price, enhancing market confidence in its future growth potential, particularly in the context of its product line expansion and strategic adjustments.
- Transparency and Compliance: The disclosure of State Street's transactions complies with the regulations set by the Irish Takeover Panel, further enhancing market trust in its compliance practices.
Analyst Views on AVDL
Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 19.93 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
0 Buy
10 Hold
0 Sell
Hold
Current: 21.500
Low
18.50
Averages
19.93
High
22.50
Current: 21.500
Low
18.50
Averages
19.93
High
22.50
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
